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a b s t r a c t
The hepatitis B virus (HBV) is formed by budding. A stretch of 22 amino acids (aa) (matrix domain, MD,
R103 – S124) in the large envelope protein L is crucial for virion formation and probably establishes
contact to the nucleocapsid. Here, we assess the impact of sequence variations at numerous individual aa
positions within the MD on virion formation. We generated panels of L mutants covering all 19 possible
aa for 11 positions and tested the capacity of these mutants to rescue virus production by an L-defective
HBV genome. At four positions (L112, R113, P117, W122), any replacement of the wild type (WT) aa
reduced virus assembly to undetectable levels. Virus production was strongly diminished by substitu-
tions at ﬁve other positions (R103, T106, S115, H116, A119). Only two tested positions (D114, Q118)
tolerated several substitutions. The restricted positions may represent promising targets for the
development of novel antiviral strategies.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The hepatitis B virus (HBV) is an enveloped DNA virus and the
prototype of the family Hepadnaviridae. Despite the existence of an
efﬁcient vaccine, this virus still chronically infects 360 million
people worldwide and causes high morbidity and mortality (Chan
and Sung, 2006). The therapy is limited to immune stimulation by
interferon and long-term treatment with nucleoside/nucleotide
analogs that block the viral reverse transcription. However, the
success of the therapy is compromised by the appearance of
resistant virus variants (Gish et al., 2012). Alternative strategies
for inhibiting virus replication are desirable to expand therapeutic
options. Since HBV encodes only one protein with enzymatic
activity, the P protein with reverse transcriptase/DNA polymerase
and RNaseH activity, protein–protein interactions during cell entry
or virion assembly may represent interesting targets for thera-
peutic intervention.
During viral replication (Beck and Nassal, 2007), an icosahedral
nucleocapsid with a diameter of 30 nm is formed in the cytosol of
the infected cell. The nucleocapsid is enveloped during budding
through an intracellular membrane containing the three viral
membrane proteins L (large), M (middle), and S (small membrane
protein) (Bruss, 2007). The L and the S proteins are required for
virion formation, while the M protein is dispensable. The three
envelope proteins are translation products of a single unspliced
open reading frame. The L protein is encoded by the entire reading
frame, while the translation of the M and S proteins starts from
two internal initiation sites at codon 120 and 175, respectively (for
genotype A used in this work). The 119 aa long region unique to L
is referred to as the preS1 domain, the 55 aa long stretch present
in L and M is named preS2, and the 226 aa long sequence of S is
present in all three proteins.
The HBV envelope proteins also form subviral lipoprotein
particles (SVP) of spherical or ﬁlamentous shape with a diameter
of 22 nm without the participation of the capsid. These particles
appear in the luminal compartment of the secretory organelles
and are released in large amounts from infected cells. The S
domains traverse the membrane four times with the N and C
termini oriented away from the cytosol. One distinctive feature of
the L protein is that it forms two different transmembrane
topologies: in the e-preS form its preS domains are located at
the luminal side of the internal membrane and in the i-preS form
the preS domains are at the cytoplasmic side (in i-preS, probably,
the ﬁrst hydrophobic domain in the S part is not traversing the
membrane) (Bruss et al., 1994; Ostapchuk et al., 1994; Prange and
Streeck, 1995).
Several experimental observations are consistent with the
model that a stretch of 22 aa between R103 and S124 of the
i-preS form of L, referred to as the matrix domain (MD), contacts
the HBV nucleocapsid during envelopment. (i) The formation of
the i-preS conformation can be prevented by fusing an N-terminal
secretion signal to L which cotranslationally translocates preS
across the membrane of the endoplasmic reticulum. This alters
the i-preS conformation of L to its e-preS conformation and blocks
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nucleocapsid envelopment (Bruss and Vieluf, 1995). (ii) N-terminal
truncations of L up to G102 were compatible with nucleocapsid
envelopment and release of virions (Bruss and Thomssen, 1994).
(iii) Substitutions of stretches of 4–8 aa between aa 125 and aa 171
(Bruss, 1997) as well as deletions between aa 132 and aa 234
allowed the release of enveloped nucleocapsids (Kluge et al., 2005;
Ni et al., 2010). (iv) Six out of seven double point mutations in the
MD strongly blocked virion formation (Bruss, 1997).
Candidates for MD binding sites on the capsid have been
mapped to the crystal structure of the particle (Wynne et al.,
1999) by screening point mutations of the capsid protein C (Pairan
and Bruss, 2009; Ponsel and Bruss, 2003), the single viral protein
forming the isosahedral capsid with T¼4 or T¼3 symmetry.
Mutations in two narrow areas at the base of the 2.5 nm long
spikes protruding from the capsid block capsid envelopment. It is
conceivable that the MD reaches down to one or both of these
sites and mediates the contact between capsid and envelope.
In favor of this view is that the distance between the MD and
the membrane must not be shorter than 26 aa (Kluge et al., 2005).
We asked what degree of sequence variability is possible in
individual amino acid positions of the MD without disturbing
capsid envelopment. To approach this question we mutagenized
11 individual positions of the MD to all 19 non-WT aa and tested
pools of mutants for complementation of an L negative HBV
genome. We found that some residues were totally invariable:
replacement of the WT aa by any other aa at these positions
reduced virion formation to undetectable levels.
Results
Virion quantiﬁcation in the supernatant of transiently
transfected cells
We wanted to examine the effect of mutations in the matrix
domain of the large HBV envelope protein on virion formation by
expressing the virus in Huh7 cells transiently transfected with an
HBV genomic plasmid construct (Fig. 1B). For quantitative analysis
of hepatitis B virions in the supernatant of transfected cells, we
measured viral genomic DNA by quantitative polymerase chain
reaction (qPCR). However, such a measurement is not trivial
because the plasmid used for transfection usually produces a
strong background. In addition the cells release substantial
amounts of naked capsids containing viral genomes which also
disturb the determination of virion titers by qPCR.
To ensure that the readout of the qPCR corresponds to the
amount of viral genomes in virions we combined three procedures
as described in the Material and methods section (virus quantiﬁ-
cation assay): (i) to exclude naked capsids, virions were immuno-
precipitated from the culture supernatant with antibodies against
the major envelope proteins S (anti-HBs) prior to viral DNA
preparation. To control the effectiveness of this step a sample
from cells transfected only with plasmid pSVHBV1.1LE carrying
the envelope-negative HBV genome was processed in parallel.
These cells produced no virions but naked capsids in amounts
comparable to cells expressing the WT viral genome (data not
shown). (ii) Before viral DNA preparation, the immunoprecipitate
was subjected to DNase treatment to remove unpackaged DNA.
(iii) Primers (forward primer nt 1784 – nt 1805, reverse primer nt
2005 – nt 1985) were used that bind to regions only 200 bp apart
in the original viral genome (Fig. 1A), while the binding sites for
these primers are separated by 3.5 kb in the genomic HBV plasmid
pSVHBV1.1LE used for transfection (Fig. 1B). The qPCR was
performed with very short extension times to favor the generation
of products initiated from viral genomes over products generated
from the transfected plasmids.
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Fig. 1. Plasmid maps. (A) Map of the HBV genome. The inner two circles
represent the complete () strand covalently linked at its 5' end to the P
protein (black square) and the incomplete (þ) strand, respectively. The black
disk labels the position of the polyA signal. The gray rectangles together with
one or two dots denote direct repeats I and II, respectively. The two arrows
show the positions of the sense (gray) and antisense (black) primers used for
qPCR. The outer circle segments represent open reading frames. (B) Map of
plasmid pSVHBV1.1LE . The plasmid carries a 1.1 mer terminal redundant (TR)
copy of the HBV genome. Transcription of the pregenomic RNA is initiated at
the SV40 early promoter (SV40). The sites for hybridization of the two primers
shown in panel (A) are indicated. The two asterisks indicate the position of two
nonsense mutations in the preS1 and S open reading frame, respectively, which
are both silent in the P reading frame. (C) Expression vector for the synthesis
of all three HBV envelope proteins. Codons 2 to 36 of preS1 were deleted
(triangle). (D) Expression vector for the synthesis of the S protein. All numbers
refer to nucleotides in the HBV genome sequence.
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The selectivity of this qPCR for viral genomes relative to the
plasmid used for transfectionwas demonstrated as follows: a plasmid
(pHBV1.5) containing the uninterrupted HBV target sequence from nt
1784 to nt 2005 was used as a surrogate for the genome in virions.
This plasmid was quantiﬁed as expected with high sensitivity by the
qPCR. However, the measured amounts for the genomic plasmid
pSVHBV1.1LE were approximately 3000 fold (103.5) lower than the
amounts applied to the assay (Fig. 2A).
For phenotypic characterization of matrix domain mutations
we cotransfected a viral genome unable to direct the synthesis
of functional envelope proteins due to two stop mutations in
the corresponding open reading frame (pSVHBV1.1LE) with an
expression vector (pSV45-57) for the missing envelope proteins
L, M, and S carrying the mutation of the matrix domain (Fig. 1C).
Codons 2–36 of the preS1 region were deleted in this plasmid
because they are dispensable for virion formation (Bruss and
Thomssen, 1994) but their presence reduces the amount of
secreted virions in a dose dependant fashion when the L protein
is overexpressed relative to S and M protein (Persing et al., 1986).
In addition, the ratio of L to S protein generated by plasmid pSV45-
57 was unfavorable for optimal virion production. Therefore, the
expression plasmid pSVBX24H for the synthesis of the small
envelope protein S (Fig. 1A) was cotransfected to adjust the L: S
ratio to an optimal level.
Since we planned to use pools of MD mutants in the virion
detection assay, we were concerned that non-functional mutants
in the pool could suppress a functional mutant in a transdominant
negative way. To address this issue we cotransfected different
ratios of a plasmid directing the synthesis of N-terminal truncated
wild type (WT) L (pSV45-57) with a plasmid encoding the non-
functional, transdominant negative MD mutant I1 containing a
partial substitution of the MD (Bruss, 1997) and used the culture
supernatant in the virion quantiﬁcation assay (Fig. 2B). The WT
alone produced approximately 106.3 virions/ml culture superna-
tant. The envelope-negative HBV genome without cotransfection
of envelope expressing plasmids is unable to direct virion forma-
tion (Bruss and Ganem, 1991) but generated a signal which would
correspond to approximately 103.3 virions/ml (Fig. 2B, column
labeled ‘m’). This signal was considered as the background of the
assay. When the negative MD mutant was expressed in the
absence of WT L approximately 104.2 virions/ml were found
(approximately 1% of the WT signal). Apparently, the MD mutant
I1 was not totally blocked in nucleocapsid envelopment but was
100 times less effective than the WT. Former characterizations of
this mutant were done by a radioactive endogenous polymerase
assay (Bruss, 1997) which was less sensitive. Surprisingly, a 1:1
mixture of WT and mutant consistently gave slightly larger
amounts of virions than the WT alone which cannot be explained
by us. Cotransfection of as low as 12.5% WT L and 87.5% mutant L
resulted in virion amounts comparable to the transfection with
100% WT L. Even 3.1% WT L/96,9% mutant L was sufﬁcient to
achieve a signal 10-fold stronger than the signal from the transfec-
tion with 0% WT L/100% mutant L. We concluded that it would be
possible and more efﬁcient to test pools of 19 mutants (all possible
non-WT aa at a given position). If just one mutant in the pool
(approximately 5%) would be fully functional a signal at least 10-
fold over background should be achieved.
Testing of the impact of sequence variations at individual positions of
the matrix domain with pools of mutants
Eleven positions (R103, T106, L112, R113, D114, S115, H116,
P117, Q118, A119, and W122) of the 22 aa long matrix domain were
chosen, and pools of mutants representing all possible amino acid
substitutions were generated for each position. We arbitrarily
excluded the proline rich region (107PISPP) and a few positions
at both ends of the MD from this analysis. The resulting 11 pools of
plasmids were tested in the virion quantiﬁcation assay (Fig. 3A)
described above. Four pools (L112, R113, P117, W122) resulted in
signals corresponding to only 1–2% of the signal generated by WT
L protein. We conclude that the WT aa were required at these
positions for efﬁcient virion formation and that any other aa
drastically reduced the level of virion formation. Two pools
(D114 and Q118) showed relatively high signals around 50–60%
of WT suggesting that several different aa at these positions were
compatible with a functional matrix domain. The remaining
5 pools (R103, T106, S115, H116, and A119) gave signals around
10% of WT. Such a value would be expected if e.g. just one non-WT
aa of the pool would confer full matrix functionality and the other
18 aa would result in non-functional L proteins.
Testing of the impact of sequence variations at some positions of the
matrix domain with individual mutants
In-depth analysis of the impact of individual amino acid
substitutions on virus production was performed for three posi-
tions of the MD (W122, D114, and Q118) (Fig. 3B). The results of
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Fig. 2. Virion detection in the supernatant of transiently transfected cells.
(A) Different amounts of plasmid pHBV1.5 carrying a continuous stretch of
the HBV sequence 1784–2005 (dots) and of plasmid pSVHBV1.1LE (squares) as
indicated on the abscissa were quantiﬁed using the qPCR described in Materials
and methods section. Plasmid pHBV1.5 (as a surrogate for the HBV genome)
was quantiﬁed as expected with high ﬁdelity. For the HBV genomic plasmid
pSVHBV1.1LE used for transfections on the other hand an amount approximately
3000-fold lower than applied was measured. (B) A mixture of the plasmid for HBV
surface protein expression (WT with respect to the MD sequence) (Fig. 1C) and the
identical plasmid I1 carrying a substitution in MD rendering the L protein non-
functional in nucleocapsid envelopment were cotransfected in the virus quantiﬁca-
tion assay. m: Transfection with the envelope-negative genomic construct (Fig. 1B)
alone. The standard deviation is indicated, n¼3.
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the tests with the pooled mutants (Fig. 3A) led us to predict that
all mutants of W122 would be non-functional whereas various
amino acid substitutions at position 114 and 118 would retain
functionality. These expectations were conﬁrmed: all tested 18
non-WT aa at position W122 resulted in an L protein defective in
nucleocapsid envelopment. (The W122T mutant is not included
because it turned out later in the project that this mutant carried a
frameshift mutation in L.) On the other hand the substitution of
D114 by several aa like E, H, I, M, Q allowed virion formation to
levels above 60% of the WT signal. Also the exchange of residue
Q118 by F, N, W, and Y was compatible with at least 50% virion
production relative to WT.
Stable expression of L point mutants
We then evaluated whether MD substitution mutants are
efﬁciently expressed and are capable of co-assembling with M
and S proteins within intracellular membrane. To this end we
investigated the incorporation of mutants into subviral particles
released from cells transfected with the L expression vector alone
(Fig. 1C) by western blotting (Fig. 4). The incorporation of WT
amounts of the L mutant into secreted subviral particles would
indicate protein stability and coassembly competence with M and
S protein close to WT. We were not able to test all 201 mutants but
we tested all 18 mutants of position W122 (Fig. 4A) and all
substitutions of the other 10 MD positions with phenylalanine
(Fig. 4B). Since the L background carried a deletion of aa 2–36, the
truncated L derivatives ran very close to M on the SDS-PAGE but
could still be identiﬁed. All L proteins with W122 mutations were
detected at similar levels as the WT L protein in both lysates and
supernatants of cells. Also, all phenylalanine mutations in 10 MD
positions allowed efﬁcient incorporation of L into subviral parti-
cles. The S protein levels could be used as internal controls for
transfection efﬁciency and gel loading. The amounts of M varied
relative to S, apparently some mutations inﬂuenced M expression.
Overall, the result showed that L protein stability and coassembly
with HBV envelope proteins was not sensitive to point mutations
in the MD. Therefore, it is likely that a negative phenotype of an
MD mutant in the virion quantiﬁcation assay indicates a defect in
nucleocapsid envelopment.
Variability of the preS sequences retrieved from databases
A large number of complete HBV genome sequences carrying a
preS1/preS2/s open reading frame with correct length were avail-
able from the NCBI database (3579 unique entries). We compared
the preS sequences and counted the occurrence of all 20 aa at each
position (Table Appendix A, Supplementary material). In Fig. 5 the
number of different aa appearing at each aa position between aa
70 and aa 141 are shown. Amino acids appearing only once were
ignored to reduce the risk that non-functional genomes were
included which e.g. were packaged into virions by transcomple-
mentation of a coinfecting WT virus.
The analysis revealed the following: the region can be divided
into 4 areas: an N-terminal area from position 70 to 83 where, on
the average, 3.5 different aa were found more than once per
position; a central left area between position 84 and 91 with
8.3 different aa per position; a central right area from position 92
to 124 with again lower variability (4.0 different aa per position);
and a C-terminal area with slightly higher variability from position
125 to 141 (5.7 different aa per position). The MD maps to the C-
terminal part of the central right area (position 103 to 124).
The two positions characterized as being variable (D114 and
Q118) showed different features in the sequence comparison: D114
was also relatively weakly conserved with only 82% of all sequences
carrying aspartate at this position. And ﬁve other aa were found
more than once at position 114. The second variable position Q118
was relatively conserved among the 3579 sequences, 99% of all
sequences carried a glutamine at this position. Only 10H, 6 L,
and 2R could be found beside the consensus aa, and these
residues are not among those allowing the highest virion formation
levels in vitro (F, N, W, Y).
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Fig. 3. Inﬂuence of MD mutations on virion formation. (A) Eleven pools containing
all 19 possible point mutations at the indicated MD positions were separately used
in the virus quantiﬁcation assay. One hundred % signal on the ordinate was reached
when L protein with WT MD was cotransfected. (B) Single mutants from pools
W122, D114 and Q118 were cotransfected in the virus quantiﬁcation assay. The
standard deviation is indicated, n¼3.
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Inspection of the four positions of the MD characterized in this
work as being crucial for virion formation (Fig. 3A) showed that
these positions were also conserved among the stored sequences.
However, at residue 112 a glycine is present in 879 sequences
instead of the consensus aa leucine. We separately tested the
L112G mutation and found very low virion formation (twice over
background, data not shown). Apparently, this variation results in
low functionality in our HBV isolate.
Discussion
In the present study we analyzed the effect of point mutations
in the matrix domain of the HBV L protein on virion assembly.
Surprisingly, in four out of eleven tested positions of the MD the
exchange of the WT aa by any other aa destroyed detectable virion
formation. This demonstrates a remarkable invariability in this
region and ﬁts to a similar invariability of the corresponding
matrix binding domain (MBD) on the HBV capsid (Pairan and
Bruss, 2009), where the exchange of individual aa on the capsid
surface to a large number of non-WT residues also blocked
envelopment.
It is not known howmany L proteins are involved in or required
for the envelopment of a nucleocapsid. The virion envelope
probably contains between 360 and 400 surface proteins
(Dryden et al., 2006; Seitz et al., 2007). The molar ratio of L:M:S
is approximately 1:1:4 (Heermann et al., 1984). Therefore roughly
60–70 L proteins are present in virions. It is possible that all L
chains are in the i-preS form during budding or that already half of
the molecules switched their topology to the e-preS form. In this
case only 30–35 L molecules have their preS domains oriented
towards the capsid. When L mutant I1 impaired in nucleocapsid
envelopment was mixed with a WT L protein as low as 12.5% WT
was sufﬁcient to allow almost WT levels of virion formation
(Fig. 2A). This would correspond to just 4 to 9 functional L proteins
per virion envelope. However, it is not known whether non-
functional L proteins are excluded from the budding process
leading to an accumulation of functional L at the site of capsid
envelopment.
The variability of certain MD residues characterized in this
work often matched the conservation of MD positions in HBV
genomes isolated from patients (Fig. 5). However, for some
positions this comparison gave puzzling results. E.g. L112 did not
tolerate any mutation in the pool (Fig. 3A), and the individual
L112G mutant resulted in very low virus production. However, 804
sequences from the database carried a glycine at this position.
Why glycine was not tolerated in our HBV isolate could not be
answered. And for position Q118 several other aa resulted in
approximately 50% of WT virus production in vitro (Fig. 3B).
However, this residue is relatively conserved in the database.
Possibly, changes in the overlapping open reading frame for the
viral polymerase by mutations in this codon limit its variability
(Jones et al., 2014). In our assay system the L protein was provided
in trans and mutations in the MD had no inﬂuence on the
polymerase. It is also possible that residue Q118 is conserved
due to another pivotal function of L that is not relevant for in vitro
virion formation. A further possibility is that the underlying DNA
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Fig. 4. Detection of L mutants in cell culture supernatants. (A) The expression
vector for HBV envelope protein synthesis (Fig. 1C) carrying a mutation of preS
codon 122 for replacement of the WT tryptophan residue by the indicated aa was
used for transfection of Huh7 cells. Cell culture supernatants were harvested,
the HBV envelope proteins were separated by polyacrylamide gel electrophoresis
and visualized by western blotting with an anti-HBs antibody. (B) Like in (A) but
the indicated codons were replaced by codons for tryptophan. S: unglycosylated S
(24 kDa), gS: N-glycosylated S (27 kDa), gM: single N-glycosylated M (33 kDa),
ggM: double N-glycosylated M (36 kDa), L: unglycosylated L (here 36 kDa due to
the N-terminal deletion of aa 2–36), gL: N-glycosylated L (here 39 kDa). Numbers
on the left indicate the position and molecular weight of marker proteins.
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sequence is required for M protein expression. The M protein is
not required for virion morphogenesis and a speciﬁc function of M
in the viral lifecycle is not known, however, the M protein is
conserved in all mammalian hepadnaviruses.
Structural proteins assemble during virion morphogenesis in
the virus producing cell but they have to disassemble in the newly
infected cell in order to release the viral genome. The correct
execution of both processes requires a delicate equilibrium of the
binding forces between viral structural components (Ceres and
Zlotnick, 2002; Tan et al., 2013), and mutations in viral proteins are
deleterious if they destroy the balance between these opposing
processes. This study suggests that the MD in the L protein has a
very limited potential to mutate without losing function. The
invariant amino acid positions might represent convenient targets
to interfere with virus replication by small molecules.
Materials and methods
Plasmids
The plasmid pSVHBV1.1LE (Fig. 1B) carries a terminal redun-
dant 1.1-mer copy of an HBV genome, genotype A (Valenzuela
et al., 1980), starting with nucleotide 1816 and terminating
with nucleotide 1980 (numbering of the 3221 bp long HBV DNA
sequence starts with the deoxycytidin residues of the unique EcoRI
site in the preS2 region). The redundant region has a length of 165
nucleotides. Codon 52 of the preS1 and codon 15 of the S open
reading frame were mutated to nonsense codons (TGG to TAG and
TTA to TGA, respectively) to block the expression of functional
envelope proteins. Both mutations are silent in the overlapping
open reading frame for the viral DNA polymerase. Transcription
initiated from the Simian Virus 40 early promoter directly upstream
of the HBV sequence and terminated by the HBV polyA signal in the
3' redundancy generates an RNA corresponding to the viral prege-
nomic RNA. The plasmid was generated by a deletion in the 3'
redundancy of plasmid pSVHBV1.5LE- (Kluge et al., 2005). Plasmid
pSVHBV1.5LE is named pHBV1.5 in the current work.
Plasmid pSV45-57 (Fig. 1C) directs the expression of an L
protein with a deletion of aa 2–aa 36 of the preS1 region and
WT M and S proteins. Plasmid I1 is identical to plasmid pSV45-57
but carries a substitution in the region encoding the MD. The
corresponding L mutant has a substitution of the peptide N99 to
Q104 by the aa sequence PASGIRIPE (Bruss, 1997). Plasmid
pSVBX24H (Fig. 1D) directs the expression of the S protein.
Mutagenesis
For the introduction of all 19 non-WT aa at a ﬁxed position of
the matrix domain plasmid pSV45-57 was used together with a
mixture of 19 oligonucleotides representing the desired 19 point
mutations in one reaction with the TransfomerTM Site-Directed
Mutagenesis Kit (Clontech, Saint-Germain-en-Laye, France).
Sequencing of 70–80 molecular clones usually resulted in the
identiﬁcation of 12–17 different mutants. Missing mutants were
generated by using individual mutant oligonucleotides for the
same procedure.
Cell culture, transfection, harvest
Huh7 cells grown in 6-well dishes were transiently transfected
with a total amount of 1 mg of plasmid using Fugene 6, Fugene HD,
or X-tremeGene HP (Roche, Rotkreuz, Switzerland) according to
the manufacturer's instructions. Cotransfections were performed
with an equal molar ratio of plasmids. After transfection, the
culture supernatant was removed, the cells were washed once
with 2 ml of PBS and 2 ml of fresh medium was added to the cells.
Five days post transfection the culture supernatant was harvested
and centrifuged for 10 min at 13,000 rpm. From the supernatant
750 ml was used for immunoprecipitation or 40 ml for western
blotting. The cells on the dish were washed with 1 ml of PBS and
lysed by adding 0.5 ml of lysis buffer (50 mM Tris–HCl pH 7.5,
100 mM NaCl, 20 mM ethylendiamintetraacetate, 0.5% (v/v) Non-
idet P40) and incubated on ice for 10 min. The cell lysate was
collected and spun at 13,000 rpm for 10 min. Forty microlitre of
the supernatant was used for western blotting.
Virus quantiﬁcation assay
To immunoprecipitate virions from cell culture supernatants of
transfected HuH7 cells, 25 ml of protein G Plus agarose beads
(Santa Cruz Biotechnologies) were washed three times with PBS
and incubated with 1 ml of sheep polyclonal anti-HBs serum (gift
from Wolfram Gerlich, Giessen) in an appropriate volume of PBS
on a rotator for 6 h at 4 1C. After another washing step with PBS,
750 ml of cell culture supernatant was added and binding of the
antigen to the anti-HBs occurred during overnight rotation at 4 1C.
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Fig. 5. Variability in the preS domain among sequences from the NCBI database. The consensus sequence from 3579 HBV genomes retrieved from the NCBI database
between the preS positions 70 and 141 is indicated at the bottom. The MD is underlined. The isolate used in this work has the following differences in this region relative to
the consensus sequence: L74I, G75L, P89S, A90T, A91I, T115S. The residues analyzed in this work (Fig. 3A) are indicated by crosses (only the WT aa allowed capsid
envelopment), circles (the corresponding pools of L mutants resulted in low virus production), and squares (the corresponding pools of L mutants resulted in high virus
production). Numbers on the ordinate show how many different aa could be found in more than one sequence from the database at the position indicated on the abscissa.
The gray vertical bars divide the region into four parts displaying different levels of sequence variability. The gray horizontal bars show the average value of all data points in
the corresponding region.
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The beads were washed three times with PBS and the amount of
residual plasmid DNA from the transfection was further dimin-
ished by a treatment with DNase (Qiagen, Hamburg, Germany). For
this purpose, the beads were suspended in 87 ml of PBS, 10 ml of
buffer supplied by the manufacturer and 2.5 ml of DNase (30
Kunitz units) and incubated at room temperature for 30 min. To
inactivate the DNase and to release the HBV genomes, the beads
were ﬁnally resuspended in 45 ml of PBS, 50 ml of 2 proteinase K
buffer (20 mM Tris-Cl pH 7.5, 20 mM EDTA, 2% (w/v) SDS) and
50 mg of proteinase K (Applichem, Darmstadt, Germany), and
incubated at 56 1C for 3 h. After three phenol/chloroform extrac-
tions the viral DNA was ethanol precipitated and the pellet was
dissolved in 30 ml of water.
The extracted viral DNA was used for quantiﬁcation of the HBV
genome by a quantitative PCR using the forward primer 5'GGCA-
TAAATTGGTCTGCGCACC hybridizing to the region between nt
1784 and nt 1805 on the HBV genome and the reverse primer
5'GCTGAGGCGGTGTCTAGGAGA hybridizing to the region between
nt 2005 and nt 1985 on the HBV genome. Ten microlitre of
SYBRGreen I Master (Roche, Penzberg, Germany), 1 ml each of a
20 mM solution of the two primers, and 8 ml of either template DNA
or water were mixed and treated in a Roche LightCycler 480 II
using the LightCycler 480 software release 1.5.0 SP4 (version
1.5.0.39). The temperature program was 5 min 95 1C/40 (20 s
95 1C/10 s 60 1C/10 s 72 1C).
Western blotting
Forty microlitre of the cleared cell culture supernatant or lysate
of transfected HuH7 cells were denatured and reduced with
sodium dodecylsulfate and dithiothreitol and used for electro-
phoresis through 12% polyacrylamide gels. The proteins in the gel
were transferred onto a nitrocellulose membrane (Trans-Blot Pure
Nitrocellulose Membrane, 0.45 mm, Biorad, Munich, Germany) by
semi-dry blotting. Envelope proteins were detected with the
mouse monoclonal antibody HB1 against a linear epitope (aa
120–125) in the S protein (courtesy provided by Aurelia Zvirbliene,
Vilnius University, Lithuania).
Comparison of HBV sequences
DNA sequences were retrieved from the NCBI nucleotide
database by searching for “hepatitis B virus complete genome”.
The data set contained 5088 entries in December 2013. However,
numerous items did not represent complete HBV genomes. There-
fore, this set was ﬁrst ﬁltered based on the sequence length (3221
nt for genotype A, 3215 nt for genotypes B, C, F, and H, 3182 nt for
genotype D, 3212 nt for genotype E, and 3248 nt for genotype G)
resulting in 3768 entries. Next, 49 redundant sequences were
deleted. From these genomes the preS1/preS2/S open reading
frame was translated starting with the methionine at position 12
for genotype A and the homologous positions in the other
genotypes. Entries that did not translate to a 389 aa long peptide
were deleted leaving 3579 unique full length sequences. The
occurrence of all 20 aa was counted for each position of the
protein (Table Appendix A, Supplementary material). The number
of different aa found more than once at each position between 70P
and 141F was determined (Fig. 5). All extractions from the
retrieved data set and calculations were done by self-written
computer programs. These programs will be made available on
request.
Acknowledgments
We thank Ke Zhang (Institute for Virology, Technical University
of Munich, Germany) for his help to develop the qPCR assay,
Aurelia Zvirbliene, Vilnius University, Lithuania for providing the
monoclonal anti-HBs antibody HB1, and Ruth Brack-Werner
(Helmholtz-Zentrum München) for critical reading of the
manuscript.
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2014.04.030.
References
Beck, J., Nassal, M., 2007. Hepatitis B virus replication. World J. Gastroenterol. 13,
48–64.
Bruss, V., 1997. A short linear sequence in the pre-S domain of the large hepatitis B
virus envelope protein required for virion formation. J. Virol. 71, 9350–9357.
Bruss, V., 2007. Hepatitis B virus morphogenesis. World J. Gastroenterol. 13, 65–73.
Bruss, V., Ganem, D., 1991. The role of envelope proteins in hepatitis B virus
assembly. Proc. Natl. Acad. Sci. USA 88, 1059–1063.
Bruss, V., Thomssen, R., 1994. Mapping a region of the large envelope protein
required for hepatitis B virion maturation. J. Virol. 68, 1643–1650.
Bruss, V., Vieluf, K., 1995. Functions of the internal pre-S domain of the large surface
protein in hepatitis B virus particle morphogenesis. J. Virol. 69, 6652–6657.
Bruss, V., Lu, X., Thomssen, R., Gerlich, W.H., 1994. Post-translational alterations in
transmembrane topology of the hepatitis B virus large envelope protein. EMBO
J. 13, 2273–2279.
Ceres, P., Zlotnick, A., 2002. Weak protein–protein interactions are sufﬁcient to
drive assembly of hepatitis B virus capsids. Biochemistry 41, 11525–11531.
Chan, H.L., Sung, J.J., 2006. Hepatocellular carcinoma and hepatitis B virus. Semin.
Liver Dis. 26, 153–161.
Dryden, K.A., Wieland, S.F., Whitten-Bauer, C., Gerin, J.L., Chisari, F.V., Yeager, M.,
2006. Native hepatitis B virions and capsids visualized by electron cryomicro-
scopy. Mol. Cell 22, 843–850.
Gish, R., Jia, J.D., Locarnini, S., Zoulim, F., 2012. Selection of chronic hepatitis B
therapy with high barrier to resistance. Lancet Infect. Dis.12, 341–353.
Heermann, K.H., Goldmann, U., Schwartz, W., Seyffarth, T., Baumgarten, H., Gerlich,
W.H., 1984. Large surface proteins of hepatitis B virus containing the pre-s
sequence. J. Virol. 52, 396–402.
Jones, S.A., Clark, D.N., Coa, F., Tavis, J.E., H.J., 2014. Comparative analysis of hepatitis
B virus polymerase sequences required for viral RNA binding, RNA packaging,
and protein priming. J. Virol. 88, 1564–1572.
Kluge, B., Schlager, M., Pairan, A., Bruss, V., 2005. Determination of the minimal
distance between the matrix and transmembrane domains of the large
hepatitis B virus envelope protein. J. Virol. 79, 7918–7921.
Ni, Y., Sonnabend, J., Seitz, S., Urban, S., 2010. The pre-s2 domain of the hepatitis B
virus is dispensable for infectivity but serves a spacer function for L-protein-
connected virus assembly. J. Virol. 84, 3879–3888.
Ostapchuk, P., Hearing, P., Ganem, D., 1994. A dramatic shift in the transmembrane
topology of a viral envelope glycoprotein accompanies hepatitis B viral
morphogenesis. EMBO J. 13, 1048–1057.
Pairan, A., Bruss, V., 2009. Functional surfaces of the hepatitis B virus capsid. J. Virol.
83, 11616–11623.
Persing, D.H., Varmus, H.E., Ganem, D., 1986. Inhibition of secretion of hepatitis B
surface antigen by a related presurface polypeptide. Science 234, 1388–1391.
Ponsel, D., Bruss, V., 2003. Mapping of amino acid side chains on the surface of
hepatitis B virus capsids required for envelopment and virion formation.
J. Virol. 77, 416–422.
Prange, R., Streeck, R.E., 1995. Novel transmembrane topology of the hepatitis B
virus envelope proteins. EMBO J. 14, 247–256.
Seitz, S., Urban, S., Antoni, C., Bottcher, B., 2007. Cryo-electron microscopy of
hepatitis B virions reveals variability in envelope capsid interactions. EMBO
J. 26, 4160–4167.
Tan, Z., Maguire, M.L., Loeb, D.D., Zlotnick, A., 2013. Genetically altering the
thermodynamics and kinetics of hepatitis B virus capsid assembly has profound
effects on virus replication in cell culture. J. Virol. 87, 3208–3216.
Valenzuela, P., M. Quiroga, J. Zaldivar, R. Gray, W. Rutter, 1980. The nucleotide
sequence of the hepatitis B viral genome and the identiﬁcation of the major
viral genes. In: Proceedings of the UCLA Symposium on Molecular and Cellular
Biology, vol. 18, pp. 57–70.
Wynne, S.A., Crowther, R.A., Leslie, A.G., 1999. The crystal structure of the human
hepatitis B virus capsid. Mol. Cell 3, 771–780.
B. Schittl, V. Bruss / Virology 458-459 (2014) 183–189 189
